Table 1 Basic demographic characteristics
From: A study of hospitalized COVID-19 patients with AKI in a setting of multiracial developing country
Basic characteristic | Number (n = 1529), (%) |
|---|---|
Gender | |
 Male | 759 (49.6%) |
 Female | 770 (50.4%) |
Age | 55 (IQR:36–66) |
Race | |
 Malay | 909 (59.5%) |
 Chinese | 310 (20.3%) |
 Indian | 244 (16%) |
 Others | 66 (4.3%) |
Comorbidities | |
 Diabetes | 500 (32.7%) |
 Hypertension | 621 (40.6%) |
 Chronic kidney disease | 85 (5.6%) |
Medications | |
 ARB/ACE inhibitor | 278 (18.2%) |
 SGLT2 | 34 (2.2%) |
 Metformin | 303 (19.8%) |
 NSAID | 128 (8.4%) |
Acute kidney injury | |
 No | 1206 (78.9%) |
 Yes | 323 (21.1%) |
Stages AKI (KDIGO, 2012) | |
 1 | 250 (16.3%) |
 2 | 32 (2.1%) |
 3 | 41 (2.7%) |
Dialysis | |
 No | 1514 (99.02%) |
 Yes | 15 (0.98%) |
AKI recovery | |
 No | 133 (41.2%) |
 Yes | 190 (58.8%) |
ICU admission | |
 No | 1199 (78.4%) |
 Yes | 330 (21.6%) |
Covid vaccination | |
 No | 1337 (88%) |
 Yes | 182 (12%) |
Types of vaccination | |
 Pfizer | 127 (8.4%) |
 AstraZeneca | 27 (1.8%) |
 Sinovac | 28 (1.8%) |
Number of vaccinations | |
 One dose | 72 (4.7%) |
 Two doses | 107 (7.1%) |
 Three doses | 3 (0.2%) |
Death | |
 No | 1394 (91.2%) |
 Yes | 135 (8.8%) |
Pneumonia | |
 No | 602 (39.4%) |
 Yes | 924 (60.6%) |
Ventilation | |
 No | 1403 (91.8%) |
 Yes | 126 (8.2%) |
Types of ventilation | Â |
 Invasive ventilation | 94 (6.2%) |
 Non-invasive ventilation | 32 (2%) |